Talampanel (LY300164) 是一种口服的选择性 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) 受体拮抗剂，具有抗癫痫活性。
| Cas No. | 161832-65-1 |
| 别名 | (8R)-7-乙酰基-5-(4-氨基苯基)-8,9-二氢-8-甲基-7H-1,3-二氧杂环戊烯并[4,5-H][2,3]苯并二氮杂卓,GYKI-53773; LY-300164 |
| Canonical SMILES | C[C@@H]1CC2=C(C=C(OCO3)C3=C2)C(C4=CC=C(N)C=C4)=NN1C(C)=O |
| 分子式 | C19H19N3O3 |
| 分子量 | 337.37 |
| 溶解度 | DMSO : ≥ 100 mg/mL (296.41 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED). Target: AMPA [1]in vitro: Talampanel is a glutamate receptor inhibitor with anti-seizure activity.in vivo: Talampanel reduces motoneuronal calcium in a mouse model of ALS, but its effi cacy declines as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective. [2] References:
[1]. Langan YM, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003 Jan;44(1):46-53.
[2]. Paizs M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12(5):340-344. |
